Truth: Clinical Supply Is Often The First To See The Whole Picture

By Melinee Stalder, sr. manager, global clinical supply chain, Novocure

Clinical supply is one of the only functions that sees the full operational reality of a trial — and one of the last to be brought in when critical decisions are made.

By the time a study reaches execution, supply has already translated strategy into physical commitments: manufacturing slots are booked, packaging is defined, distribution lanes are mapped. While other functions are still adjusting assumptions, supply is operating against fixed constraints.

That’s why clinical supply often sees risk first.

We see when enrollment projections don’t match manufacturing timelines.
We see when protocol design creates packaging complexity that won’t scale.
We see when country activation plans ignore regulatory and import realities.

And by the time these misalignments become visible to the broader team, they are no longer risks — they are delays.

Reality: Misalignment Isn’t Accidental

In most organizations, misalignment isn’t caused by lack of communication. It’s caused by how decisions are made.

Clinical operations optimizes for speed and enrollment.
Regulatory focuses on compliance and approvals.
CMC works within manufacturing and release constraints.
Finance manages cost and budget cycles.

Each function is doing its job. But no single function owns the translation of assumptions into operational reality.

That gap is where clinical supply lives.

And when that gap isn’t actively managed, supply becomes the point where misalignment finally surfaces — often too late to fix cleanly.

What Clinical Supply Sees First

1. Forecasts That Don’t Reflect Reality

Forecasts often look aligned — until they’re translated into production.

A 20% increase in enrollment may seem manageable on paper. In practice, it can mean:

• missed manufacturing windows
• expedited packaging at higher cost
• constrained inventory buffers.

By the time enrollment accelerates, supply has already lost the lead time needed to respond efficiently.

2. Protocol Decisions That Create Hidden Complexity

Protocol changes are evaluated for scientific and clinical impact, but not always for operational feasibility.

Small decisions — dosing schedules, visit windows, cohort expansions — can:

• multiply SKU requirements
• complicate labeling strategies
• reduce flexibility in distribution.

These impacts are rarely visible until supply planning begins. At that point, options are limited and trade-offs become unavoidable.

3. Country Plans That Ignore Activation Reality

Adding a country can appear incremental from a clinical perspective.

From a supply perspective, it can trigger:

• new regulatory submissions
• country-specific labeling requirements
• import/export constraints
• additional depots or distribution routes.

What looks like a simple expansion can reset timelines entirely if not aligned early.

Why Other Functions Don’t See It

These gaps persist because each function operates with different signals and timelines.

• Clinical teams work with projections.
• Regulatory works with submission milestones.
• CMC works with production schedules.
• Supply works with irreversible commitments.

Supply is forced to convert assumptions into action earlier than anyone else. That’s why we feel the impact of misalignment first —not because supply is more important but because supply is where strategy meets constraint.

Common Failure Patterns

Across trials, the same patterns repeat:

• Enrollment accelerates without triggering supply adjustments.
• Packaging is finalized before regulatory requirements are fully aligned.
• CMC delays are communicated after supply plans are already locked.
• Quality events stall because decision ownership is unclear.
• Budget constraints delay procurement without visibility to downstream impact.

These failures rarely happen in isolation. More often, they begin with missed or delayed signals, most commonly when enrollment data fails to drive timely forecast updates. Supply plans continue to operate on assumptions that have already changed. When this signal breaks down in practice, the failure is not isolated, and it cascades through the end-to-end supply system. For example, an enrollment spike captured in IRT may not be reflected in the demand forecast until the next scheduled data refresh cycle, which means supply planning continues to operate on outdated assumptions. By the time the updated forecast is reviewed, manufacturing slots that could have been adjusted have already been consumed. This forces either expedited production or acceptance of constrained inventory buffers.

Those constraints then flow downstream into packaging and labeling decisions, where flexibility is reduced due to locked configurations, and ultimately into distribution, where depot allocation and regional stock positioning no longer match actual trial demand. At that point, the system is no longer correcting variance but absorbing it through cost, time, and operational inefficiency.

None of these issues are inherently catastrophic. What makes them disruptive is the lack of early, enforced alignment and clear trigger points to turn signals into action.

What Actually Works

Alignment doesn’t improve through more meetings. It improves through clear operational controls.

1. Defined Trigger Points

Establish nonnegotiable thresholds that force cross-functional engagement:

• enrollment variance beyond a set percentage
• new country additions
• dosing or protocol changes.

If the trigger is hit, alignment is required — no exceptions.

2. Integrated Road Maps

Maintain a shared, rolling view across clinical, CMC, regulatory, and supply that connects:

• manufacturing timelines
• release schedules
• regulatory milestones
• supply readiness.

Misalignment is easiest to fix when it’s visible early.

3. Rapid Decision Frameworks

For deviations, temperature excursions, or supply disruptions:

• Define decision owners in advance.
• Set response timelines (e.g., 24-hour resolution targets).
• Remove ambiguity during execution.

Speed matters, but clarity matters more.

4. Scenario-Based Planning

Every trial should begin with multiple supply scenarios:

• expected case
• accelerated enrollment
• expanded scope.

When changes occur — and they always do — teams adjust from a prepared position instead of reacting under pressure.

Clinical Supply As The Early Warning System

Clinical supply sits at the intersection of science, operations, logistics, and compliance.

We are required to make decisions earlier.
We are required to commit resources sooner.
We are required to translate assumptions into execution.

That positioning makes supply a natural early warning system for trial risk, but only if supply is included early enough to influence decisions, not just react to them.

When supply is brought in late, teams inherit constraints.
When supply is embedded early, teams can shape better outcomes.

The Cost Of Waiting

When misalignment reaches supply, the cost is already increasing:

• Timelines compress.
• Options narrow.
• Costs rise.
• Risks compound.

And ultimately, the impact extends beyond operations.

Every delay in supply readiness can delay patient access.
Every disruption can affect trial continuity.

Operational misalignment is not just a process issue — it’s a patient impact.

The Bottom Line

If clinical supply is reacting, the trial is already behind.
If supply is surprised, alignment has already failed.

Organizations that treat supply as a strategic partner — rather than a downstream function — run more predictable, efficient trials with fewer disruptions.

Clinical supply doesn’t just deliver product. It reveals where the system is misaligned, often before anyone else can see it. The question is whether organizations are willing to act on that visibility early enough to matter.

About The Author:

Melinee Stalder is a senior manager in global clinical supply chain with extensive experience supporting clinical trials and complex global study operations. She specializes in translating enrollment, protocol, and regulatory assumptions into efficient, compliant, and patient‑focused investigational supply strategies. With a strong background in drug supply planning, logistics, and cross‑functional execution, Melinee works at the intersection of clinical operations, CMC, regulatory, and supply to bring early visibility to operational risk. Her work is grounded in operational excellence, collaboration, and continuous improvement, with a consistent focus on protecting trial timelines and patient access.